A new epidemiological mapping study from Imperial College London, published in The Lancet Infectious Diseases, reveals that artemisinin-resistant malaria parasites are no longer confined to isolated geographic pockets but are spreading across East Africa at an alarming rate. The research documents resistant Plasmodium falciparum strains now present in 72% of East African regions surveyed, compared to established endemicity in Southeast Asia at 95%. This geographic expansion poses a critical threat to artemisinin-based combination therapies (ACTs), which have served as the cornerstone of malaria treatment for nearly two decades. Experts warn that without urgent intervention—including enhanced surveillance systems, investment in drug quality assurance, and accelerated development of next-generation antimalarials—treatment efficacy could be severely compromised across the region. The findings underscore the need for coordinated regional action to prevent further resistance spread and protect existing therapeutic options.
Was this article helpful?
